229 related articles for article (PubMed ID: 26728648)
1. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
Hale ME; Zimmerman TR; Eyal E; Malamut R
J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
[TBL] [Abstract][Full Text] [Related]
2. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
Hale ME; Ma Y; Malamut R
J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
[TBL] [Abstract][Full Text] [Related]
3. Twelve-month, open-label assessment of long-term safety and abuse potential of hydrocodone extended-release formulated with abuse-deterrence technology in patients with chronic pain.
Hale ME; Zimmerman TR; Ma Y; Malamut R
J Opioid Manag; 2015; 11(5):425-34. PubMed ID: 26535970
[TBL] [Abstract][Full Text] [Related]
4. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
[TBL] [Abstract][Full Text] [Related]
6. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
Wen W; Taber L; Lynch SY; He E; Ripa S
J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled study of the efficacy and safety of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets for acute postoperative pain.
Singla N; Margulis R; Kostenbader K; Zheng Y; Barrett T; Giuliani MJ; Chen Y; Young JL
Phys Sportsmed; 2015 May; 43(2):126-37. PubMed ID: 25796986
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
Hale ME; Zimmerman TR; Ma Y; Malamut R
Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
Taber L; Lynch SY; He E; Ripa SR
Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.
Lee JH; Lee CS;
Clin Ther; 2013 Nov; 35(11):1830-40. PubMed ID: 24183364
[TBL] [Abstract][Full Text] [Related]
11. Relationship between change in pain intensity and functional outcomes in patients with chronic pain receiving twice daily extended-release hydrocodone bitartrate.
Argoff C; Arnstein P; Stanos S; Robinson CY; Galer BS; Gould E; Gammaitoni A
J Opioid Manag; 2015; 11(5):417-24. PubMed ID: 26535969
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain.
Hale ME; Laudadio C; Yang R; Narayana A; Malamut R
J Pain Res; 2015; 8():623-36. PubMed ID: 26396543
[TBL] [Abstract][Full Text] [Related]
13. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone.
Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A
Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
Bartoli A; Michna E; He E; Wen W
Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
[TBL] [Abstract][Full Text] [Related]
15. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
Hale ME; Ahdieh H; Ma T; Rauck R;
J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
Wen W; Sitar S; Lynch SY; He E; Ripa SR
Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.
Bond M; Schoedel KA; Rabinovich-Guilatt L; Gasior M; Tracewell W; Malamut R; Ma Y; Webster LR
Pain Med; 2018 Aug; 19(8):1597-1612. PubMed ID: 29016880
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study.
Uberall MA; Mueller-Schwefe GH; Terhaag B
Curr Med Res Opin; 2012 Oct; 28(10):1617-34. PubMed ID: 22970658
[TBL] [Abstract][Full Text] [Related]
20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
